Challenges for the development of new treatments for severe asthma: A pharmaceutical perspective

Current Pharmaceutical Design

Volumn 17, Issue 7, 2011, Pages 699-702

  Knowles, Richard G ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Biomarkers; Collaboration; Difficult asthma; Phenotypes; Refractory asthma; Segmentation

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; CIGARETTE SMOKE; CORTICOSTEROID; GAMMA INTERFERON; INTERLEUKIN 5; MEPOLIZUMAB; MONTELUKAST; OMALIZUMAB; OZONE; PREDNISOLONE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ARTICLE; ASTHMA; COHORT ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MEGADOSE; DRUG SAFETY; ENZYME INHIBITION; EOSINOPHIL; FUNDING; HUMAN; INNATE IMMUNITY; KNOWLEDGE MANAGEMENT; MEDICAL EDUCATION; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REIMBURSEMENT; STUDY DESIGN; TH1 CELL; TH17 CELL; TRANSCRIPTOMICS;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 79954542305     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795429019     Document Type: Article

References (13)

1. Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI), Thorax Published online November 23, 2010 in advance of the print journal, doi: 10.1136/thx.2010.153643
2. Hamid, Q. Current challenges and management of chronic severe asthma, Current Pharmaceutical Design, Chapter N, To be determined 2011.
3. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368: 780-93.
4. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-24.
5. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315-23.
6. Hastie, AT, Moore, WC, Meyers, DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes, J Allergy Clin Immunol 2010; 125: 1028-36.
7. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176: 1062-71.
8. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Resp J 2006; 27: 483-494.
9. SARP network, http://www.severeasthma.org/
10. UBIOPRED consortium, http://www.ubiopred.european-lungfoundation.org/
11. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-84.
12. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-93.
13. Mepolizumab phase IIb study: http://clinicaltrials.gov/ct2/show/NCT01000506